Table 2 Outcomes after 8, 24 and 52 weeks of treatment with Secukinumab
All patients | AS patients | PsA patients | |
|---|---|---|---|
Effectiveness | |||
Week 8 | |||
ASDAS-CRP or DAS28-CRP value, mean ± SD (median ± IQR) | - | 2.5 ± 0.8 (2.1 ± 1.5) | 4.2 ± 0.85 (4 ± 0.6) |
(at least) Low disease activity, N. (%) | 15 (18) | 11 (38) | 4 (7)** |
Inactive disease or Remission, N. (%) | 0 (0) | 0 (0) | 0 (0) |
Change in ASDAS-CRP or DAS28-CRP, mean ± SD (median ± IQR) | - | -1.1 ± 0.75 (-1.5 ± 1.6) | -1.6 ± 0.9 (-1.6 ± 0.95) |
(at least) CII or Moderate response, N. (%) | 67 (79) | 19 (65.5) | 48 (86)* |
Major improvement or Good response, N. (%) | 4 (5) | 0 (0) | 4 (7) |
Week 24 | |||
ASDAS-CRP or DAS28-CRP value, mean ± SD (median ± IQR) | - | 1.7 ± 0.8 (1.2 ± 0.6) | 2.7 ± 0.8 (2.5 ± 0.85) |
(at least) Low disease activity, N. (%) | 58 (68) | 19 (65.5) | 39 (70) |
Inactive disease or Remission, N. (%) | 39 (46) | 13 (45) | 26 (46) |
Change in ASDAS-CRP or DAS28-CRP, mean ± SD (median ± IQR) | - | -2 ± 0.8 (-2.3 ± 0.65) | -3.1 ± 1.1 (-3.1 ± 1.3) |
(at least) CII or Moderate response, N. (%) | 70 (82) | 21 (72) | 49 (87.5) |
Major improvement or Good response, N. (%) | 55 (65) | 16 (55) | 39 (70) |
Week 52 | |||
ASDAS-CRP or DAS28-CRP value, mean ± SD (median ± IQR) | - | 1.3 ± 0.5 (1.2 ± 0) | 2.2 ± 0.7 (2.2 ± 0.45) |
(at least) Low disease activity, N. (%) | 64 (75) | 20 (69) | 44 (79) |
Inactive disease or Remission, N. (%) | 57 (67) | 19 (65.5) | 38 (68) |
Change in ASDAS-CRP or DAS28-CRP, mean ± SD (median ± IQR) | - | -2.3 ± 0.6 (-2.4 ± 0.3) | -3.6 ± 0.9 (-3.6 ± 1.2) |
(at least) CII or Moderate response, N. (%) | 67 (79) | 20 (69) | 47 (84) |
Major improvement or Good response, N. (%) | 63 (74) | 19 (65.5) | 44 (79) |
Retention rate (Drug survival after 52 weeks), N. (%) | 64 (75) | 20 (69) | 44 (79) |
Safety | |||
Serious adverse events, N. | 0 | 0 | 0 |
Injection-site reactions, N. | 4 | 1 | 3 |